Even though the management keep saying forward looking statement as in "if approved", the management had already invested large amount of capital into commercializing ADS-5102. From Alfred Merriweather explanation of the difference in general and administrative expenses for the recent quarter between $13.1 million and $8.1 million-"This increase reflects cost associated with building the administrative and commercial capabilities in preparation for commercialization."
From Rajiv Patni, "The efficacy measure used was the MDS-UPDRS Part IV score, which is a measure of dyskinesia and OFF time. The treatment benefit of ADS-5102 was rapid, substantial and durable out to 88 weeks. We also presented data from a group of patients who switched from amantadine immediate release to ADS-5102.These data showed that patients previously on amantadine immediate release experienced a 35% reduction in dyskinesia and OFF time when switched to ADS-5102. This treatment effect was comparable to that experienced by amantadine-naive patients switched from placebo to open-label ADS-5102." It suggested that direct comparison of the amantadine immediate release and ADS-5102 has been done internally by the management.
Disclosure: I am/we are long ADMS.
Additional disclosure: I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.